| Nome |
# |
|
PARP Inhibitors in Ovarian Cancer, file e27ce42f-ad3d-2581-e053-d805fe0acbaa
|
2.367
|
|
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions, file e27ce429-ba9f-2581-e053-d805fe0acbaa
|
506
|
|
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome, file e27ce42f-f839-2581-e053-d805fe0acbaa
|
480
|
|
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer, file e27ce42f-d9bd-2581-e053-d805fe0acbaa
|
344
|
|
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy, file e27ce426-ac70-2581-e053-d805fe0acbaa
|
341
|
|
Metastatic breast cancer subtypes and central nervous system metastases., file e27ce426-f2c2-2581-e053-d805fe0acbaa
|
283
|
|
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer, file e27ce42b-163a-2581-e053-d805fe0acbaa
|
260
|
|
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer?, file e27ce429-b1f4-2581-e053-d805fe0acbaa
|
248
|
|
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity, file e27ce42c-a76a-2581-e053-d805fe0acbaa
|
244
|
|
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer, file e27ce42a-da57-2581-e053-d805fe0acbaa
|
237
|
|
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?, file e27ce42b-59b1-2581-e053-d805fe0acbaa
|
217
|
|
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers, file e27ce42f-be83-2581-e053-d805fe0acbaa
|
165
|
|
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy, file e27ce427-fb48-2581-e053-d805fe0acbaa
|
160
|
|
Androgen receptor status predicts development of brain metastases in ovarian cancers, file e27ce42c-05d1-2581-e053-d805fe0acbaa
|
155
|
|
Recent advances in the development of breast cancer vaccines., file e27ce427-0b7e-2581-e053-d805fe0acbaa
|
151
|
|
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer, file e27ce426-fd7a-2581-e053-d805fe0acbaa
|
146
|
|
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis, file e27ce430-45cf-2581-e053-d805fe0acbaa
|
145
|
|
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer., file e27ce429-b730-2581-e053-d805fe0acbaa
|
134
|
|
Adoptive immunotherapy against ovarian cancer, file e27ce429-4f51-2581-e053-d805fe0acbaa
|
127
|
|
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers, file e27ce42d-d5ef-2581-e053-d805fe0acbaa
|
125
|
|
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer, file ed30a300-d9fe-4ce9-83e8-d76fcb4d73b0
|
125
|
|
Role of cyclin-dependent kinase inhibitors in endometrial cancer, file e27ce42f-f83c-2581-e053-d805fe0acbaa
|
124
|
|
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells, file e27ce435-09ce-2581-e053-d805fe0acbaa
|
118
|
|
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications, file e27ce42e-cec0-2581-e053-d805fe0acbaa
|
110
|
|
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience, file e27ce430-2b28-2581-e053-d805fe0acbaa
|
101
|
|
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21), file e27ce434-d9c6-2581-e053-d805fe0acbaa
|
96
|
|
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer, file e27ce42c-bace-2581-e053-d805fe0acbaa
|
94
|
|
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents., file e27ce42d-e147-2581-e053-d805fe0acbaa
|
93
|
|
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy, file e27ce431-cc2b-2581-e053-d805fe0acbaa
|
93
|
|
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy, file e27ce42e-0aba-2581-e053-d805fe0acbaa
|
92
|
|
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells., file e27ce42f-6b49-2581-e053-d805fe0acbaa
|
92
|
|
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience, file e27ce42c-d5e9-2581-e053-d805fe0acbaa
|
90
|
|
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer, file e27ce430-12da-2581-e053-d805fe0acbaa
|
87
|
|
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas, file e27ce42f-d57d-2581-e053-d805fe0acbaa
|
84
|
|
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report, file e27ce42e-fddd-2581-e053-d805fe0acbaa
|
83
|
|
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma, file e27ce42f-58bf-2581-e053-d805fe0acbaa
|
82
|
|
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey, file e27ce434-e28a-2581-e053-d805fe0acbaa
|
81
|
|
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells, file e27ce42e-d784-2581-e053-d805fe0acbaa
|
77
|
|
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience, file e27ce42f-d57f-2581-e053-d805fe0acbaa
|
72
|
|
Ovarian cancer immunotherapy: Turning up the heat, file e27ce42f-f83b-2581-e053-d805fe0acbaa
|
72
|
|
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors, file e27ce434-d591-2581-e053-d805fe0acbaa
|
65
|
|
Is there a role for immunotherapy in ovarian cancer?, file e27ce42f-cca2-2581-e053-d805fe0acbaa
|
63
|
|
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives, file e27ce42f-d57e-2581-e053-d805fe0acbaa
|
63
|
|
Translational research in ovarian cancer, file e27ce431-4297-2581-e053-d805fe0acbaa
|
58
|
|
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality, file e27ce435-1099-2581-e053-d805fe0acbaa
|
50
|
|
Immunotherapy in cervix cancer, file e27ce434-c204-2581-e053-d805fe0acbaa
|
49
|
|
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group, file e27ce435-0df0-2581-e053-d805fe0acbaa
|
40
|
|
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs), file e27ce42e-de99-2581-e053-d805fe0acbaa
|
21
|
|
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?, file e27ce435-6fd0-2581-e053-d805fe0acbaa
|
20
|
|
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey, file e27ce435-855a-2581-e053-d805fe0acbaa
|
20
|
|
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition, file e27ce435-a799-2581-e053-d805fe0acbaa
|
19
|
|
Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report, file 7c224205-7e98-4dfa-80b5-5f8745410fab
|
14
|
|
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy, file e27ce434-f492-2581-e053-d805fe0acbaa
|
14
|
|
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study, file e3009967-8951-4d63-ac33-d2369dd472c6
|
14
|
|
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia, file 0803831b-13e7-4b14-b95e-e2b3b03de2d5
|
13
|
|
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups, file e27ce434-feca-2581-e053-d805fe0acbaa
|
13
|
|
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature, file e27ce435-83c1-2581-e053-d805fe0acbaa
|
13
|
|
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w), file e27ce434-c166-2581-e053-d805fe0acbaa
|
11
|
|
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study, file 5947a685-bb1f-47be-89be-fbfb095ba792
|
10
|
|
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers, file e4d8c451-e503-4043-a58b-c8bd8446711a
|
9
|
|
Veliparib: a new therapeutic option in ovarian cancer?, file e27ce42e-2c92-2581-e053-d805fe0acbaa
|
8
|
|
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22), file 62c3d437-a1d4-4fda-b997-b8fbad23d912
|
7
|
|
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study, file 8de7f72e-fb7f-4db1-8fe0-2b690271564c
|
7
|
|
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs), file e27ce42e-cf86-2581-e053-d805fe0acbaa
|
7
|
|
Biomarkers of central nervous system involvement from epithelial ovarian cancer, file e27ce434-ce4f-2581-e053-d805fe0acbaa
|
7
|
|
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, file 5aea012d-a6d0-42f4-a6e4-7603180689b0
|
5
|
|
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer, file e27ce427-3a76-2581-e053-d805fe0acbaa
|
5
|
|
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib, file e27ce426-c5d7-2581-e053-d805fe0acbaa
|
4
|
|
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis, file 2d154b6e-d8ce-40a0-8917-c4a35289612e
|
3
|
|
Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers, file 339364dd-b4ab-47de-92ff-e2d0033eb01a
|
3
|
|
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience, file 8f2258b7-dc9a-4e76-8ba8-6e3673949448
|
3
|
|
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma, file 9109526f-b862-4655-954f-22b3a0e3b56e
|
2
|
|
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors, file be64f5a3-0826-412c-9a03-2f74dc5a7cb9
|
2
|
|
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer., file e27ce426-e99b-2581-e053-d805fe0acbaa
|
2
|
|
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer, file e27ce428-f629-2581-e053-d805fe0acbaa
|
2
|
|
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers, file a70e325d-eb14-4f04-90bc-359b3e602db8
|
1
|
|
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study, file c1f29fbf-cbd3-4df8-9e6e-63d89c33963a
|
1
|
|
Potential of afatinib in the treatment of patients with HER2-positive breast cancer., file e27ce426-f44e-2581-e053-d805fe0acbaa
|
1
|
|
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series, file e27ce42c-e4ca-2581-e053-d805fe0acbaa
|
1
|
|
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models, file e27ce42e-de9a-2581-e053-d805fe0acbaa
|
1
|
|
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature, file e27ce431-e586-2581-e053-d805fe0acbaa
|
1
|
|
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer, file e27ce432-5e86-2581-e053-d805fe0acbaa
|
1
|
|
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society, file e61348dc-dc5a-4282-8e44-1333c59647d7
|
1
|
|
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial, file f0db6949-f933-42dd-aae1-b89ab48ec607
|
1
|
|
Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features, file f6cf104e-22e7-4433-8f90-34c31a3d57c3
|
1
|
| Totale |
9.357 |